Forpatients with myeloid neoplasms (usually myelodysplastic syndrome/myeloproliferativeneoplasms) with eosinophilia and rearranged PDGFRB, the recommendedimatinib dose is 400 mg daily, which reflects the dose consistently used in severalcase series with excellent outcomes.6 The gene discussed is PDGFRB; the disease is myelodysplastic syndrome.